Approved & therapeutic
Eptifibatide
Integrilin
Eptifibatide is a synthetic cyclic heptapeptide glycoprotein IIb/IIIa inhibitor, used as an antiplatelet agent in acute coronary syndrome and during percutaneous coronary intervention.
Also known as: eptifibatide acetate
- Status
- Eptifibatide is approved by the U.S. FDA and has official prescribing information.
- Evidence
- Approved labeling. Official prescribing information exists, based on clinical trials in people.
- Half-life
- Approximately 2.5 hours; platelet function recovers within about 4 hours of discontinuation.
- How it's taken
- Intravenous bolus followed by continuous infusion
- Mechanism
- Other
How Eptifibatide works
Eptifibatide contains a KGD sequence that binds the platelet glycoprotein IIb/IIIa receptor, the final common pathway of platelet aggregation. Blocking this receptor prevents fibrinogen from cross-linking adjacent platelets, so aggregation cannot proceed regardless of which upstream agonist activated the platelet. Its structure derives from a disintegrin found in pygmy rattlesnake venom.
What research has looked at
- Blocks the final common pathway of platelet aggregation, so it works irrespective of the activating stimulus.
- Rapid onset and rapid, predictable offset — platelet function recovers within about four hours of stopping the infusion.
- Reversible, non-covalent receptor binding, unlike abciximab.
Evidence level: Approved labeling. Official prescribing information exists, based on clinical trials in people. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Bleeding is the principal risk, including major bleeding and intracranial haemorrhage.
- Thrombocytopenia, occasionally profound and occurring within hours of first exposure; platelet counts must be checked early.
- It is renally cleared and the infusion rate must be reduced in renal impairment; it is contraindicated in dialysis dependence.
- Hypotension.
- It has no oral form and no outpatient use.
Sources
- FDA approved-drug listing for eptifibatide · U.S. Food & Drug Administration
- DailyMed prescribing information for eptifibatide · NIH · DailyMed
- PubMed research on eptifibatide glycoprotein IIb IIIa · NIH · National Library of Medicine
- DrugBank record for eptifibatide · DrugBank
Track Eptifibatide in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Eptifibatide FAQ
What is Eptifibatide?
Eptifibatide is a synthetic cyclic heptapeptide glycoprotein IIb/IIIa inhibitor, used as an antiplatelet agent in acute coronary syndrome and during percutaneous coronary intervention.
How does Eptifibatide work?
Eptifibatide contains a KGD sequence that binds the platelet glycoprotein IIb/IIIa receptor, the final common pathway of platelet aggregation. Blocking this receptor prevents fibrinogen from cross-linking adjacent platelets, so aggregation cannot proceed regardless of which upstream agonist activated the platelet. Its structure derives from a disintegrin found in pygmy rattlesnake venom.
Is Eptifibatide FDA approved?
Yes. Eptifibatide is approved by the U.S. FDA and has official prescribing information. Evidence level: approved labeling. Official prescribing information exists, based on clinical trials in people.
What is the half-life of Eptifibatide?
Reported half-life: Approximately 2.5 hours; platelet function recovers within about 4 hours of discontinuation.
How is Eptifibatide taken?
Intravenous bolus followed by continuous infusion.
What side effects have been reported with Eptifibatide?
Reported in the sources: Bleeding is the principal risk, including major bleeding and intracranial haemorrhage; Thrombocytopenia, occasionally profound and occurring within hours of first exposure; platelet counts must be checked early; It is renally cleared and the infusion rate must be reduced in renal impairment; it is contraindicated in dialysis dependence; Hypotension; It has no oral form and no outpatient use.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.